Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer.

ABSTRACT:

Objectives

Intravesical Bacillus Calmette-Guérin (BCG) therapy is a gold standard for patients with high-risk non-muscle invasive bladder cancer (NMIBC). Although a long-lasting therapeutic response is observed in most patients, BCG failure occurs in 30%-50% of patients and a progression to muscle-invasive disease is found in 10%-15%. Therefore, predicting high-risk patients who might not benefit from BCG treatment is critical. The purpose of this study was to identify, whether the presence of specific oncogenic mutations might be indicative of BCG treatment response.

Methods

Nineteen high-grade NMIBC patients who received intravesical BCG were retrospectively enrolled and divided into "responders" and "non-responders" groups. Tissue samples from transurethral resection of b

SUBMITTER: Francesca B 

PROVIDER: S-EPMC11915050 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature